#JPM23: Reg­u­la­to­ry un­cer­tain­ty? What about M&A? Da­ta rule? Alessan­dro Masel­li and John Car­roll take out their crys­tal balls

End­points ed­i­tor and founder John Car­roll sat down the Catal­ent CEO Alessan­dro Masel­li to talk about what’s ahead in 2023. Right or wrong, this cov­ers all the big is­sues faced by bio­phar­ma. This tran­script has been edit­ed for brevi­ty and clar­i­ty.

John Car­roll:

I think 2022 had to be one of the worst years ever for crys­tal balls. You went in­to 2022 think­ing all sorts of nice things about what was ahead, not think­ing about a Eu­ro­pean land war, maybe not think­ing that the Fed­er­al Re­serve was go­ing to be jack­ing up in­ter­est rates as fast as they could to get ahead of in­fla­tion. Just a tremen­dous num­ber of macro­eco­nom­ic is­sues that were out there. The sud­den and com­plete col­lapse of sup­port on the mar­kets in Nas­daq for biotech. A lot of dar­lings in the in­dus­try that had been out there for a while sud­den­ly found them­selves mov­ing from a re­al­ly hot mar­ket to a re­al­ly cold mar­ket all of a sud­den and had to make a lot of dif­fer­ent changes in terms of strate­giz­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER